Automated design of ligands to polypharmacological profiles
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - Nature, 2012 - econpapers.repec.org
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
[HTML][HTML] Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - Nature, 2012 - ncbi.nlm.nih.gov
The clinical efficacy and safety of a drug is determined by its activity profile across multiple
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - Nature, 2012 - ideas.repec.org
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - …, 2012 - pubmed.ncbi.nlm.nih.gov
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
[PDF][PDF] Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - 2012 - academia.edu
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
[引用][C] Automated design of ligands to polypharmacological profiles
J BESNARD, G FILIPPO RUDA… - Nature …, 2012 - pascal-francis.inist.fr
Automated design of ligands to polypharmacological profiles CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
[引用][C] Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - Nature, 2012 - cir.nii.ac.jp
Automated design of ligands to polypharmacological profiles | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - …, 2012 - ui.adsabs.harvard.edu
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
Automated design of ligands to polypharmacological profiles
J Besnard, GF Ruda, V Setola, K Abecassis… - Nature, 2012 - infoscience.epfl.ch
The clinical efficacy and safety of a drug is determined by its activity profile across many
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …
proteins in the proteome. However, designing drugs with a specific multi-target profile is both …